Specific genotypes of human papillomavirus in 125 high-grade squamous lesions and invasive cervical cancer cases from Congolese women

被引:0
作者
Luc Magloire Anicet Boumba
Lahoucine Hilali
Mustapha Mouallif
Donatien Moukassa
Moulay Mustapha Ennaji
机构
[1] Université Hassan II Mohammedia,Laboratoire de Virologie, Microbiologie et Qualité/ETB, Faculté des Sciences et Techniques
[2] Université Hassan 1er Settat,Laboratoire d’Agroalimentaire et Santé, Département de Biologie Appliquée, Faculté des Sciences et Techniques
[3] Hôpital Général de Loandjili,Laboratoire d’Analyses Médicales et Morphologiques
[4] Université Hassan 1er Settat,Institut Supérieur des Sciences de la santé
来源
BMC Public Health | / 14卷
关键词
Specific-genotype; HPV; HSIL; ICC; Southwestern Congo;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 189 条
[1]  
De Vuyst H(2013)The burden of human papillomavirus infections and related diseases in sub-saharan Africa Vaccine 31 F32-46
[2]  
Alemany L(2010)Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Canc 127 2893-2917
[3]  
Lacey C(1999)Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 189 12-19
[4]  
Chibwesha CJ(2011)Human Papillomavirus Testing in the Prevention of Cervical Cancer J Natl Cancer Inst 103 1-16
[5]  
Sahasrabuddhe V(2009)A review of human carcinogens-Part B: biological agents Lancet Oncol 10 321-322
[6]  
Banura C(1998)Natural History of Cervicovaginal Papillomavirus Infection in Young Women New England Journal of Medicine 338 423-428
[7]  
Ferlay J(2010)Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection Journal of the National Cancer Institute 102 315-324
[8]  
Shin HR(2009)Human papillomavirus, current vaccines, and cervical cancer prevention Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG 38 69-80
[9]  
Bray F(2006)Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial Lancet 367 1247-1255
[10]  
Forman D(2009)The HPV vaccines–which to prefer? Obstetrical & gynecological survey 64 345-350